Home
Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.
Novo's Xultophy and Sanofi's Soliqua both combine a long-lasting insulin with a so-called GLP-1 medicine that stimulates insulin production in the pancreas.
Officials at the Danish and French companies said on Tuesday the rival treatments would be sold at discounts to the combined price of the component ingredients.
The combination products are viewed by analysts as having substantial sales potential and the two drugmakers hope they will boost revenue at a time when insulin prices are under intense pressure in the key U.S. market, the world's biggest.
http://www.reuters.com/article/us-novo-nordisk-fda-idUSKBN13G2K5
Easy money for big pharma the present dietary guidelines for diabetics will ensure that
Novo's Xultophy and Sanofi's Soliqua both combine a long-lasting insulin with a so-called GLP-1 medicine that stimulates insulin production in the pancreas.
Officials at the Danish and French companies said on Tuesday the rival treatments would be sold at discounts to the combined price of the component ingredients.
The combination products are viewed by analysts as having substantial sales potential and the two drugmakers hope they will boost revenue at a time when insulin prices are under intense pressure in the key U.S. market, the world's biggest.
http://www.reuters.com/article/us-novo-nordisk-fda-idUSKBN13G2K5
Easy money for big pharma the present dietary guidelines for diabetics will ensure that
